Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment
Most patients with rapid PSADT underwent secondary treatment within 1 year after BCR. More contemporary patients treated with early secondary treatment had better outcomes than historical data from patients who had delayed treatment. Whether these results reflect the benefits of early secondary treatment or overall improvements in prostate cancer outcomes over time requires further study.
Authors
- Jasmina Ivanova (ORCID: https://orcid.org/0000-0002-4028-9676)
- Stephen J. Freedland (ORCID: https://orcid.org/0000-0002-8104-6419)
- Krishnan Ramaswamy (ORCID: https://orcid.org/0000-0003-0890-0268)
- David H. Russell (ORCID: https://orcid.org/0000-0003-0830-3914)
- Angela Lax (ORCID: https://orcid.org/0000-0001-9577-8904)
- Hongbo Yang (ORCID: https://orcid.org/0000-0003-0753-1931)
- Wei Gao (ORCID: https://orcid.org/0000-0002-4088-3210)
- Agnes Hong
Institutions
- Cedars-Sinai Medical Center (US)
- Pfizer (United States) (US)
- Durham VA Medical Center (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Prostate Cancer and Prostatic Diseases
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1038/s41391-024-00894-0
- Citations
- 5
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Pfizer
- Astellas Pharma US
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders